NewsRx

Search our medical news database

Dyslipidemia

Report: Dyslipidemia drug-treated population to grow 4% annually

Published in Obesity and Diabetes Week, September 27th, 2004

Decision Resources, Inc., forecasts that the overall dyslipidemia drug-treated population will increase by 4% annually.

Primary factors driving the rise in drug treatment in this population include increasing awareness of its coronary heart disease risk coupled with the availability of low-cost, generic statin substitutes to treat these patients.

The new Pharmacor study entitled "Dyslipidemia" also finds that Pfizer and Merck plan to fight back against generic erosion of atorvastatin and simvastatin, two leading statins.

"The launch of Pfizer's atorvastatin/torcetrapib and atorvastatin/amlodipine, and of Merck/Schering-Plough's...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook